Watch Nicolas Girard talk about treatment sequencing!
GIOTRIF® (afatinib) has a manageable AE profile with dose modification proven to reduce AEs without compromising efficacy

*A grouped term.
This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy
This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information on Giotrif®.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that the registration status and approved product labels of Giotrif® may not be the same in different countries.
Information on this website is derived from the Summary of Product Characteristics (SPC) for Giotrif® in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and have read and understood this disclaimer.
*A grouped term.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue?
If you wish to report an adverse event (AE) after treatment with one of our products, please select your site from the link below. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.
Boehringer Ingelheim local websites